GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Small and Large Bowel/mt-sDNA is supior tool for CRC screening

mt-sDNA is supior tool for CRC screening

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated November 1, 2025

Quick Answer

Yes, multitarget stool DNA (mt-sDNA) is considered a superior tool for colorectal cancer (CRC) screening, especially for younger adults under 50, based on the findings of the study outlined in the context. Here's why mt-sDNA is superior: 1.


Yes, multitarget stool DNA (mt-sDNA) is considered a superior tool for colorectal cancer (CRC) screening, especially for younger adults under 50, based on the findings of the study outlined in the context. Here's why mt-sDNA is superior:

1. **Higher Follow-Up Colonoscopy Adherence**:

  • Among individuals aged 45–49 with a positive stool-based test, follow-up colonoscopy (FU-CY) adherence within 12 months was significantly higher for mt-sDNA users (85.0%) compared to fecal immunochemical test/occult blood test (FIT/FOBT) users (35.2%). This indicates that mt-sDNA testing leads to better compliance with recommended follow-up procedures.

2. **Faster Follow-Up Timeliness**:

  • The mean time to colonoscopy after a positive test was shorter for mt-sDNA users (74.5 days) compared to FIT/FOBT users (90.8 days). This faster follow-up is crucial for timely detection and prevention of colorectal cancer progression.

3. **Benchmark Achievement**:

  • mt-sDNA users exceeded the US Multi-Society Task Force’s benchmark of 80% adherence for post-screening colonoscopy completion, demonstrating its effectiveness in ensuring adherence to screening protocols.

4. **Early Follow-Up Rates**:

  • Within the first 90 days after testing, a significantly higher percentage of mt-sDNA users (62.9%) completed their follow-up colonoscopy compared to FIT/FOBT users (22.8%). Early follow-up is critical for detecting early-onset colorectal cancer and improving outcomes.

5. **Target Population**:

  • The study specifically focused on adults aged 45–49, a group increasingly recognized for its risk of early-onset colorectal cancer. mt-sDNA testing proved to be a more effective screening tool for this younger population.

6. **Study Scale and Robustness**:

  • The findings are backed by robust data from the Komodo Research Data (KRD) database and Exact Sciences Laboratory (ESL), which together cover over 165 million lives. This large claims-based dataset adds credibility to the study's conclusions.

In summary, mt-sDNA testing outperforms FIT/FOBT in terms of follow-up adherence, timeliness, and overall effectiveness as a screening tool for colorectal cancer prevention in younger adults. Its ability to ensure timely and consistent follow-up after a positive test makes it a superior choice for CRC screening, particularly for individuals under 50.

Related Q&A

Anal High-Grade Squamous Intraepithelial Lesions (HSIL): BJS | March 2026

Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...

Post-Infection DGBI (PI-DGBI): Gut | July 2026

Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...

FMT in IBS: Gastroenterology | July 2026

Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...

Laparoscopic vs Open Adhesiolysis for Bowel Obstruction: JAMA Surgery | June 2026

Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...

DPP-4 Inhibition Targets the Gut–Brain Axis in Parkinson's Disease: Gut | July 2026

Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for...

Bedside Ultrasound Outperforms Abdominal X-Ray in Neonatal Necrotizing Enterocolitis: Frontiers in Pediatrics | July 2026

Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer